In the BioHarmony Drug Report Database
Halaven (eribulin) is a small molecule pharmaceutical. Eribulin was first approved as Halaven on 2010-11-15. It is used to treat breast neoplasms and liposarcoma in the USA. It has been approved in Europe to treat breast neoplasms and liposarcoma. The pharmaceutical is active against tubulin beta chain. Halaven’s patents are valid until 2027-01-08 (FDA).
Image (chem structure or protein)